Magrolimab and Pembrolizumab Combination Study in Hodgkin Lymphoma Initiated
A clinical trial is underway to evaluate the safety and efficacy of magrolimab combined with pembrolizumab in relapsed or refractory classic Hodgkin lymphoma.
Indication
Clinical and regulatory intelligence for Hodgkin Lymphoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.